← FDA DRUG APPROVALS

FDA ANDA · ANDA074826

ESTAZOLAM

Sponsor: NOVITIUM PHARMA

APPLICATION
ANDA074826
TYPE
ANDA
ORIGINAL APPROVAL
1997-07-03
LATEST ACTION
2023-01-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

ESTAZOLAMPrescription
ESTAZOLAM 2MG · TABLET · ORAL
ESTAZOLAMPrescription
ESTAZOLAM 1MG · TABLET · ORAL

Approval history

2023-01-17Labeling · Supplement 24 · standardAP
2021-08-02Manufacturing (CMC) · Supplement 20 · unknownAP
2021-02-05Labeling · Supplement 19 · standardAP
2019-02-06Labeling · Supplement 18 · standardAP
2016-12-16Labeling · Supplement 17 · standardAP
2008-09-09Labeling · Supplement 15AP
2007-09-16Manufacturing (CMC) · Supplement 14AP
2002-07-29Manufacturing (CMC) · Supplement 10AP
2000-04-21Manufacturing (CMC) · Supplement 6AP
2000-04-21Manufacturing (CMC) · Supplement 4AP
2000-04-21Manufacturing (CMC) · Supplement 7AP
2000-04-21Manufacturing (CMC) · Supplement 5AP
2000-01-28Manufacturing (CMC) · Supplement 8AP
1999-11-23Manufacturing (CMC) · Supplement 3AP
1998-12-09Manufacturing (CMC) · Supplement 2AP
1998-02-25Manufacturing (CMC) · Supplement 1AP
1997-07-03OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →